Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.24.2.u1
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 4,413 10,582 10,858 19,393
General and administrative 2,932 3,870 6,247 9,155
Operating expenses 7,345 14,452 17,105 28,548
Other income/(expense):        
Interest income 93 326 214 748
Foreign exchange loss 0 (3) (1) (5)
Total other income 93 323 213 743
Net loss (7,252) (14,129) (16,892) (27,805)
Other comprehensive loss:        
Unrealized (loss) gain on available-for-sale securities 1 (1) 0 3
Total comprehensive loss $ (7,251) $ (14,130) $ (16,892) $ (27,802)
Basic loss per common share (in dollars per share) $ (0.43) $ (2.27) $ (1.13) $ (4.47)
Diluted loss per common share (in dollars per share) $ (0.43) $ (2.27) $ (1.13) $ (4.47)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 16,755 6,234 14,944 6,219
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 16,755 6,234 14,944 6,219